The Academy of Medical Sciences has begun a project exploring how evidence is used to make decisions about the safety and efficacy of drugs and medical interventions.
In a statement published on 16 June, the academy said high-profile media debates on drugs such as statins had concerned its fellows and that its council had decided an evaluation of different sources of evidence, such as randomised clinical trials and observational data, would be a useful contribution to the debate.
The working group for the project is led by Michael Rutter, former vice-president of the academy. The project will begin by considering statins, but may consider infectious diseases such as Ebola as well as rare cancers.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.